The Effect of Preoperative Long Period Octreotide Combined With Postoperative Short Period Octreotide on the Complications After Pancreatectomy. A Prospective, Multicenter Clinical Trial
Primary Purpose
Pancreatic Diseases
Status
Unknown status
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Preoperative Long Period Octreotide Combined With Postoperative Short Period Octreotide
Sponsored by
About this trial
This is an interventional treatment trial for Pancreatic Diseases focused on measuring Pancreatic fistula
Eligibility Criteria
Inclusion Criteria:
- Pancreatectomy patients
Exclusion Criteria:
- Treated by chemotherapy or radiotherapy before With distant organ metastasis Cannot tolerate surgery
Sites / Locations
- National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeRecruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Combined group
Arm Description
Outcomes
Primary Outcome Measures
pancreatic fistula
delayed gastric emptying
intra-abdominal fluid collections
wound infection
Bile leak
Abdominal bleeding
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT03398941
Brief Title
The Effect of Preoperative Long Period Octreotide Combined With Postoperative Short Period Octreotide on the Complications After Pancreatectomy. A Prospective, Multicenter Clinical Trial
Official Title
The Effect of Preoperative Long Period Octreotide Combined With Postoperative Short Period Octreotide on the Complications After Pancreatectomy. A Prospective, Multicenter Clinical Trial
Study Type
Interventional
2. Study Status
Record Verification Date
January 2018
Overall Recruitment Status
Unknown status
Study Start Date
February 1, 2018 (Anticipated)
Primary Completion Date
January 1, 2019 (Anticipated)
Study Completion Date
May 1, 2019 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Chengfeng Wang
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The Effect of Preoperative Long Period Octreotide Combined With Postoperative Short Period Octreotide on the Complications After Pancreatectomy. A Prospective, Multicenter Clinical Trial
Detailed Description
The trial is funded by Cancer Foundation of China. The trial is prepared to be registered on the clinicaltrail.gov.
Quality assurance plan: every participant is enrolled or excluded by two practiced investigators. And two investigators participated in all steps of the trail, including the record of the data, and the investigators will compare the data. If the data is consistent, the investigators would record the data; if not, the data would be checked and decided by the two investigators. All the steps and data are site monitored and audited by the workers of research and financial department of National Cancer Center/ Cancer Hospital, Chinese Academy of Medical Sciences.
Data check: the investigators compare data entered into the registry against predefined rules for range or consistency with other data fields in the registry. Source data verification to assess the accuracy, completeness, or representativeness of registry data by comparing the data to external data sources, including medical records and electronic case report forms.
Data dictionary that contains detailed descriptions of each variable used by the registry, including the source of the variable, coding information, and normal ranges if relevant.
Standard Operating Procedures to address registry operations and analysis activities, such as participants recruitment, data collection, data management, data analysis, reporting for adverse events, and change management. All registry operations would be done according to specific steps, and by two practiced investigators.
Sample size assessment to specify the number of participants or participant years necessary to demonstrate an effect. According to the formula to differ advantages and disadvantages, the investigators need at least 70 participants to take part in the trail.
The investigators can recruit about 150 participants according to previous experiences.
Plan for missing data: the investigators would collect as much data as possible, and the investigators exclude the participants who cannot cooperate on recruitment. And the investigators manage situations according to statistical principles where variables are reported as missing, unavailable, "non-reported," uninterpretable, or considered missing because of data inconsistency or out-of-range results.
Statistical analysis plan: Kaplan-Meier method would be used to analyze the difference of survival time between the two groups, and the local control rate of the two groups would be compared by chi square test. Statistical analyses would be performed by using IBM SPSS Statistics(version 20; IBM, Chicago, USA). The level of significance is defined as P < 0.05.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pancreatic Diseases
Keywords
Pancreatic fistula
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
150 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Combined group
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
Preoperative Long Period Octreotide Combined With Postoperative Short Period Octreotide
Intervention Description
Long-Period Octreotide 20mg one week before operation combine Short Period Octreotide 0.3mg during postoperative five days.
Primary Outcome Measure Information:
Title
pancreatic fistula
Time Frame
three week after operation
Title
delayed gastric emptying
Time Frame
three week after operation
Title
intra-abdominal fluid collections
Time Frame
three week after operation
Title
wound infection
Time Frame
three week after operation
Title
Bile leak
Time Frame
three week after operation
Title
Abdominal bleeding
Time Frame
three week after operation
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Pancreatectomy patients
Exclusion Criteria:
Treated by chemotherapy or radiotherapy before With distant organ metastasis Cannot tolerate surgery
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Chen yingtai, PhD
Phone
+8618600258827
Email
yingtai.chen@hotmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
Zhao Yajie, PhD
Phone
+8617319303256
Email
zhaoyajielancet@qq.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Wang Chengfeng, MD
Organizational Affiliation
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Official's Role
Principal Investigator
Facility Information:
Facility Name
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
City
Beijing
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Chen Yingtai, PhD
Phone
+8618600258827
Email
yingtai.chen@hotmail.com
First Name & Middle Initial & Last Name & Degree
Zhao Yajie, PhD
Phone
+8617319303256
Email
zhaoyajielancet@163.com
First Name & Middle Initial & Last Name & Degree
Wang chengfeng, BA
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
The Effect of Preoperative Long Period Octreotide Combined With Postoperative Short Period Octreotide on the Complications After Pancreatectomy. A Prospective, Multicenter Clinical Trial
We'll reach out to this number within 24 hrs